

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO:

COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450,

ON 15 December 2004

NAME OF PERSON MAILING DOCUMENT

DATE

Attorney Docket No. P51032

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Jacques Briand

15 December 2004

Serial No.:

10/070,128

Group Art Unit No.: 1639

Filed:

27 February 2002

Examiner:

Mark Lance Shibuya

For:

Method of Using One-Dimensional and Multi-Dimensional Nuclear

Magnetic Resonance to Identify Compounds that Interact with Target

Biomolecules

Commissioner for Patents P.O. Box 1450 Alexandria VA, 22313-1450

Filing of an Information Disclosure Statement under 37 C.F.R. §1.97(c) and Certification under 37 C.F.R. §1.97(e)(1) or (e)(2)

Information Disclosure Statement. The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 in order to comply with the duty of disclosure. Their inclusion herein should not, however, be construed as an admission that any particular cited reference is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. Copies of each are enclosed, except for those references already part of the filewrapper. This statement is being filed with the required Certification and without any fee, in accordance with the provisions of 37 C.F.R. §1.97(c)(1) and (2), i.e., before a Final Action under 37 CFR §1.113 or a Notice of Allowance under 37 CFR §1.311.

ifas

Serial No.: 10/070,128 Group Art Unit No.: 1639

<u>Statement of Certification</u>. The undersigned hereby certifies that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

Respectfully submitted,

Edward R. Gimmi Attorney for Applicants Registration No. 38,891

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-4478
Facsimile (610) 270-5090
N:\text{VERG\APPS\P51032\US National\UDS Letter 2.doc}

FEE						SI	heet 1 c	of <u>1</u> .
Form PTO-144 TRAD: U.S. Department of Commerce Patent and Trademark Office				ATTY, DOCKET NO. P51032		SERIAL NO. 10/070,128		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Jacques Briand				
						-		
			U.S. PATEN	T DOCUMENTS			·	
Examiner Initial	Document Number			Name Clas		Subclass	Filing Date If Appropriate	
		<u> </u>						v
		1						
				· · · · · · · · · · · · · · · · · · ·				
		<u> </u>	<u> </u>					
<u>_</u>		FC	PEIGN PAT	ENT DOCUMENTS				
	Document	Document Date		Country Class		Subclass		
	Number						Yes	No.
				uthor, Title, Date, Pertir				
	Hajduk, et al., "NMR-Based Discovery of Phosphotyrosine Mimetics that Bind to the LCK SH2 Domain," Bioorganic and Medicinal Chemistry Letters, 9: 2403-2406 (1999).							
	Hensmann, et al.,	"Phosphope	ptide bindin	g to the N-terminal SI	12 domain	of the p85α s	subunit c	of PI
				Protein Science, 3: 102			274/520	2
	1531-1534 (1996)).	•	igands for Proteins: SA	-		,	
	Ni, et al., "Recent 517-606 (1994).	Developmen	nts in Trans	ferred Noe Methods,"	Progress in	NMR Spect	roscopy,	, 26:
	Copy of Partial El	P Search Rep	ort.					
EXAMINER				DATE CONGIDEDED				
CVAINIINEK				DATE CONSIDERED				

•EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copyof this form with next communication to applicant.

N:\ERG\APPS\P51032\US National\1449 from search report.doc